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Several edible mushrooms extracts are known to have tumour cell growth inhibitory 
potential. The objective of this work was to study this potential in extracts of Suillus 
luteus collected from the Northeast of Portugal. Various extracts were prepared and 
their effect on tumour cell growth was studied with the SRB assay in four human 
tumour cell lines: MCF-7 (breast), NCI-H460 (non-small cell lung cancer), AGS 
(gastric) and HCT-15 (colon). The methanolic extract of S. luteus was the most potent 
extract. This extract was slightly more potent in the HCT-15 cells (with mutant p53, 
GI50=17.8 ± 1.6 µg/mL) than in the other cell lines tested, which suggested that its 
effect was not p53-dependent. Indeed, in HCT-15 cells, an increase in the levels of p53 
was detected but no alterations in some of the proteins transactivated by p53 (e.g. p21 or 
Bax) were found. The extract caused an increase in the cellular levels of p-H2A.X, 
which is suggestive of DNA damage. Growth inhibition in these cells was mostly due to 
inhibition of cell proliferation and an increase in the % of cell in the G1 phase of the 
cell cycle. An increase in cell death was also found, even though to very low levels. In 
addition, this extract was not cytotoxic to primary cultures of porcine hepatocytes 
(GI50>400 µg/mL). Together, these results indicate that the S. luteus methanolic extract 
may be an interesting source of compounds that inhibit the proliferation of tumour cells 
but further studies should be carried out in order to understand its potential. 
 






The majority of new drugs have been generated from either natural products (secondary 
metabolites) or analogs inspired by them. Many drugs such as antibiotics (penicillin, 
tetracycline and erythromycin), antiparasitics (avermectin), antimalarials (quinine, 
artemisinin), lipid control agents (lovastatin and analogs), immunosuppressants for 
organ transplants (cyclosporin, rapamycins) or anticancer drugs (taxol, doxorubicin) 
have been found or produced in this way (Li & Vederas, 2009). 
Mushrooms (macrofungi) contain a vast diversity of biomolecules with nutritional 
(Kalač, 2009) and/or medicinal properties (Poucheret, Fons, & Rapior, 2006). They 
have been recognized as functional foods and as a source of compounds for the 
development of nutraceuticals or medicines, including compounds with antitumour 
properties (Zaidman, Yassin, Mahajna, & Wasser, 2005; Moradali, Mostafavi, Ghods, 
& Hedjaroude, 2007).  
The most studied compounds are high-molecular-weight ones, such as the β-glucans 
“Lentinan” from the fruiting bodies of Lentinus edodes,  “Schizophyllan” from the 
culture fluid of Schizophyllum commune, or the polysaccharopeptides PSP and 
“Krestin” (PSK) from the cultured mycelium of Coriolus versicolor (Ferreira, Vaz, 
Vasconcelos & Martins, 2010; Luk et al., 2011). Despite their commercialization, 
limited clinical studies in cancer patients have been conducted. In addition to the 
mentioned well-known medicinal mushrooms, previous work from our research group 
showed that other wild unexplored species from Portugal are notable for their promising 
antitumour potential, such as Clitocybe alexandri and Suillus collinitus. Indeed, their 
phenolic extracts (including low molecular weight compounds) showed effects on cell 
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cycle and induced apoptosis in human lung and breast cancer cell lines, respectively 
(Vaz et al., 2012a; Vaz et al., 2012b). 
Following our research in wild edible species from Northeast Portugal, the present work 
describes the cytotoxic activity of methanolic, ethanolic and boiled water extracts of S. 
luteus in various human tumor cell lines: lung, breast, colon and gastric cancer. The 
extract with the highest cell growth inhibitory activity (methanolic extract) was chosen 
to be further investigated regarding its possible mechanism of action in the most 
susceptible cell line studied (colon cancer), by evaluation of its effect on the cell cycle 
profile, cellular proliferation and apoptosis. The chemical characterization of S. luteus 
was previously reported by our research group. This mushroom presented 
protochatechuic acid (0.47 mg/100 g dry weight), cinnamic acid (0.41 mg/100), α-
tocopherol (19.14 µg/100 g), β-tocopherol (15.34 µg/100 g), γ-tocopherol (366.77 
µg/100 g), δ-tocopherol (78.51 µg/100 g), mannitol (1.29 g/100 g), trehalose (1.35 
g/100 g), polyunsaturated fatty acids (52.75%, with linoleic acid- 52.31%- as the main 
fatty acid), monounsaturated fatty acids (32.93%, with oleic acid- 31.24%- as the main 
fatty acid), and saturated fatty acids (14.32%, with palmitic acid- 10.57% as the main 
fatty acid) (Reis et al., 2011). 
 
2. Materials and Methods 
2.1. Sample collection and preparation of the extracts 
Samples of Suillus luteus (L.: Fries) Gray (edible mushroom) were collected in 
Bragança (Northeast Portugal), in autumn 2009. Taxonomic identification of sporocarps 
was made according to Coutecuisse & Duhem (2005) and representative voucher 
specimens were deposited at the herbarium of Escola Superior Agrária of Instituto 
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Politécnico de Bragança. The samples were lyophilised (Ly-8-FM-ULE, Snijders, 
Holland) and reduced to a fine powder (20 mesh). 
Enriched phenolic (methanolic and ethanolic) and polysaccharidic (boiled water) 
extracts were prepared from the lyophilised powder following the procedure previously 
described by us (Vaz et al., 2010). Briefly, to obtain the methanolic extract, the 
lyophilized sample (~2 g) was extracted twice with methanol (50 mL) mixture at -20 °C 
for 6 h. The extract was sonicated for 15 min, centrifuged at 4000 × g for 10 min, 
filtered through Whatman nº 4 paper and concentrated under reduced pressure (rotary 
evaporator Büchi R-210). To obtain the polysaccharidic (boiling water) extract, the 
lyophilized sample (~1.5 g) was extracted three times with water at boiling temperature 
(50 mL) for 2 h and subsequently filtered through Whatman No. 4 paper. The combined 
extracts were lyophilized, and then 95% ethanol (10 mL) was added and 
polysaccharides were precipitated overnight at 4 ºC. The precipitated polysaccharides 
were collected after centrifugation (Centorion K24OR- 2003 refrigerated centrifuge) at 
3100 × g for 40 min followed by filtration, and then were lyophilized, resulting in a 
crude polysaccharidic sample. The ethanolic supernatant was concentrated under 
reduced pressure, giving the ethanolic extract.  
For the subsequent assays, the extracts were re-dissolved in DMSO and the solutions 
were stored at -20 ºC until further use.  
 
2.2. Cell Culture 
2.2.1. Human tumour cell lines. The cell lines used were: NCI-H460 (lung cancer), 
AGS (gastric cancer), MCF-7 (breast cancer) and HCT-15 (colon cancer).  Cells were 
plated in RPMI 1640 medium supplemented with 5% heat-inactivated FBS (Lonza).  




2.2.2. Primary cells of porcine liver. A cell culture was prepared from a freshly 
harvested porcine liver obtained from a local slaughter house, and it was designed as 
PLP2. Briefly, the liver tissues were rinsed in Hank’s balanced salt solution containing 
100 U/mL penicillin, 100 µg/mL streptomycin and divided into 1×1 mm3 explants. 
Some of these explants were placed in 25 cm2 tissue flasks in DMEM medium 
supplemented with 10% fetal bovine serum, 2 mM nonessential amino acids and 100 
U/mL penicillin, 100 mg/mL streptomycin and incubated at 37 ºC with a humidified 
atmosphere containing 5% CO2. The medium was changed every two days. Cultivation 
of the cells was continued with direct monitoring every two to three days using a phase 
contrast microscope. The cells were cultivated in DMEM medium with 10% FBS, 100 
U/mL penicillin and 100 µg/mL streptomycin (Abreu et al., 2011). 
 
2.3. Analysis of cell growth  
The effects of the extracts on the growth of human tumour cell lines was evaluated, 
according to the procedure adopted in the NCI’s in vitro anticancer drug screening 
(Skehan et al., 1990). Each cell line was plated at an appropriate density (5.0 × 103 
cells/well for NCI-H460 and MCF-7, 1.0 × 104 cells/well for HCT-15 and 7.5 × 103 
cells/well for AGS, and 1.0×104 cells/well for PLP2) in 96-well plates and allowed to 
attach for 24 h. Cells were then treated for 48 h with various extract concentrations. The 
DMSO concentrations used presented no growth inhibitory effect in these cell lines. 
Following this incubation period, the adherent cells were fixed with 10% trichloroacetic 
acid (final concentration), stained with SRB and excess dye washed with 1 % acetic 
acid. The bound SRB was solubilised with 10 mM Tris and the absorbance was 
measured at 510 nm in a microplate reader (Multi-mode microplate synergy™ MX, 
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Biotek) and analysed with the Gen5™ software (Biotek). The concentration that 
inhibited growth in 50% (GI50) was calculated according to Monks et al. (1991) and as 
previously described by the authors (Vaz et al., 2010).  
 
2.4. Cell cycle analysis  
For the analysis of cell cycle phase distribution, HCT-15 cells were plated at 2×105 
cells/well in 6-well plates and incubated for 24 h. Cells were then incubated with 
complete medium (blank), with S. luteus methanolic extract at the GI50 and 2×GI50 
concentrations or with DMSO (control). Cells were harvested following a 24 and 48 h 
of incubation period with the extract, further fixed in 70% ethanol and kept at 4ºC until 
analysis. Prior to analysis, cells were incubated with Propidium Iodide (5 µg/mL) and 
RNase A in PBS (100 µg/ml) for 30 min on ice (Vaz et al., 2012a).  
Cellular DNA content was analyzed at the Advanced Flow Cytometry Unit 
(IBMC/INEB) using a FACS Calibur (BD) flow cytometer. Cell cycle profile was 
subsequently analysed using the FlowJo 7.2 software (Queiroz et al., 2010).  
 
2.5. Programmed cell death (TUNEL) and proliferation (BrdU) asssay 
For the TUNEL and BrdU assay, cells were plated, respectively at 7.5×104  per well in 
12-well plates, and 2×105  per well in 6-well plates, and incubated for 24 h. Cells were 
then further incubated with complete medium (blank), with S. luteus methanolic extract 
at the GI50 and 2×GI50 concentrations or with DMSO (control).  
For the TUNEL assay, cells were harvested following a 24 and 48 h incubation with the 
extract, further fixed in 4% PFA  and kept in PBS at 4 ºC until analysis. Cytospins were 
prepared and cells were permeabilized in ice cold 0.1% Triton X-100 in 0.1% sodium 
citrate for 2 min. Programmed cell death was assessed using the “in situ cell death 
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detection kit” (Roche, Basel Switzerland). Briefly, cells were incubated with the 
TUNEL reaction mix (enzyme diluted 1:20) for 1 h, as previously described (Palmeira 
et al., 2010). 
For the BrdU assay, 23 h following incubation with the extract, cells were given a pulse 
of BrdU (10 µM, Sigma) for 1 h and were then washed and fixed in 4% 
paraformaldehyde in phosphate buffer saline. Cytospins were prepared and incubated in 
2M HCl for 20 min.  They were then incubated with mouse anti-BrdU (1:10, Dako) and 
further incubated with fluorescein-labeled rabbit anti-mouse antibody (1:100, Dako), as 
previously described (Palmeira et al., 2010). 
For the analysis of slides from both the TUNEL and the BrdU assay, slides were 
mounted in Vectashield Mounting Media with DAPI (Vector Laboratories). Cells were 
observed in a DM2000 microscope (LEICA) and a semi-quantitative evaluation of the 
levels of programmed cell death or proliferation was performed by counting a minimum 
of 500 cells per slide. 
 
2.6. Protein expression analysis 
Cells were plated at 2×105 per well in 6-well plates and incubated for 24 h. They were 
then treated with complete medium (blank), the solvent of the extract (DMSO) or with 
the GI50 or 2×GI50 concentration of the methanolic extract of S. luteus and processed 48 
h later. Briefly, cells were lysed in Winman's buffer (1% NP-40, 0.1 M Tris-HCl pH 
8.0, 0.15 M NaCl and 5 mM EDTA) with EDTA-free protease inhibitor cocktail 
(Boehringer Mannheim). Proteins were quantified with the DC Protein Assay kit 
(BioRad), separated in 12% (resolving) and 5% (Stacking) tris-glycine sodium dodecyl 
sulfate (SDS)-polyacrylamide gels and transferred to a nitro-cellulose membrane (GE 
Healthcare). Membranes were incubated with the following primary antibodies for p53 
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(1:200, Calbiochem), p73 (1:500), Bax (1:500, Santa Cruz Biotechnology), p21 (1:250, 
Thermo scientific), p-H2A.X (1:200), Actin (1:2000, Santa Cruz Biotechnology), and 
then incubated with the respective secondary antibodies- horseradish peroxidase (HRP) 
conjugated (1:2000, Santa Cruz Biotechnology). The signal was detected with the 
Amersham ECL kit (GE Healthcare), Hyperfilm ECL (GE Healthcare) and Kodak GBX 
developer and fixer twin pack (Sigma), as previously described (Vasconcelos et al., 
2000). The intensity of the bands obtained in each film was further analyzed using the 
software Quantity One – 1D Analysis (Bio-Rad), as previously described (Palmeira et 
al., 2010). 
 
2.7. Statistical analysis 
Results were expressed as mean values ± standard deviation (SD) of at least 3 
independent experiments, performed in duplicate. Statistical significance was tested 
with a two tailed paired Student’s t-Test using the DMSO as a negative control. * 
Indicates p<0.05. 
 
3. Results and Discussion 
 
3.1. The methanolic extract of S. luteus presents cell growth inhibitory activity in 
various human tumour cell lines but not in primary porcine liver cells 
The enriched phenolic (methanolic and ethanolic) and polissacharidic (boiled water) 
extracts of S. luteus were screened for tumour cell growth inhibitory potential in four 
human tumour cells lines (NCI-H460, MCF-7, HCT-15 and AGS). The determined 
values of GI50 (concentrations that caused 50% cell growth inhibition) are expressed in 
Table 1. The methanolic extract was the most potent extract in all the cell lines tested, 
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since the other extracts did not reach the GI50 at the concentrations tested (up to 400 
µg/ml). Léon et al. (2008) had previously shown that suillumide, a ceramide isolated 
from the ethanolic extract of S. luteus, presented cytotoxic activity against a human 
melanoma cell line (with IC50 values of approximately 10 µM following a 72 h 
treatment). Nonetheless, in our study the ethanolic extract did not present significant 
cytotoxic activity (in the studied cell lines and up to the concentrations tested).  
S. luteus methanolic extract had previously been reported to present cytotoxic activity 
against a murine cancer cell line (Tomasi, 2004). Nevertheless, to our knowledge, this is 
the first study that shows a cytotoxic activity in human tumour cell lines.  
The cell line which was most sensitive to the effect of this extract was the HCT-15 cell 
line (GI50 = 17.75±1.6 µg/mL). Therefore, this cell line was selected to further study the 
effect of this extract. Interestingly, this extract was not cytotoxic to primary cultures of 
porcine hepatocytes (GI50 > 400 µg/mL, Table 1).  
 
3.2.The methanolic extract of S. luteus reduces the proliferation of HCT-15 cells and 
causes a cell cycle arrest in G1  
The HCT-15 cells were treated with the GI50 (17.75 µg/mL) or twice the GI50 
concentration (35.5 µg/mL) of the methanolic extract of S. luteus. The effect on cellular 
proliferation was analysed upon 24 h incubation and on cell cycle profile upon 24 h and 
48 h incubation. Results from the cell cycle profile analysis show that this extract 
caused an increase in the % of cells in the G1 phase of the cell cycle, which was more 
evident (and statistically significant) with twice the GI50 concentration, mostly 24 h 
following treatment (Figure 1A) . In addition, treatment with the extract caused a 
statistically significant decrease in the % cells in the S and G2/M phases of the cell 
cycle, when cells were treated with twice the GI50 concentration for 24 h (Figure 1A). 
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A decrease in the % cells in the S phase was also obtained when cells were treated with 
the GI50 for 24 h and a statistically significant decrease in G2/M when cells were treated 
with twice the GI50 concentration for 48h (Figure 1B).  
In agreement with this cell cycle arrest in G1, treatment of HCT-15 cells with the 
extract caused a concentration dependent decrease in cellular proliferation, which was 
very strong and statistically significant when cells were treated with twice the GI50 
concentration (Figure 2). 
 
3.3.The methanolic extract of S. luteus does not interfere with programmed cell death of 
HCT-15 cells 
The effect of the extract on programmed cell death of HCT-15 cells was investigated 
with the TUNEL assay. Treatment during 24h with the GI50 concentration or during 
24h or 48h with twice the GI50 concentration of the extract increased cell death, even 
though to very low levels (Table 2).   
 
2.4.The activity of the methanolic extract of S. luteus does not depend on p53 
The HCT-15 cell line has heterozygous mutations in the p53 tumour suppressor gene 
(O'Connor et al., 1997). Even though it would be possible that the remaining wild-type 
allele could remain functional, this cell line has been documented, by a reporter assay 
monitoring p53-dependent transactivation in cells, to lack functional p53 (Falck et al., 
2001). Therefore, the fact that the methanolic extract of S. luteus was more potent in 
this cell line than in the other studied cell lines indicated that the effect of this extract 
was, at least in this cell line, not p53 dependent. Indeed, even though HCT-15 cells 
treated with the extract presented an increase in p53 expression (Figure 3A), there was 
no increase in some of the proteins transactivated by wild-type p53, such p21 or Bax 
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(Figure 3B and 3C). In fact, the levels of Bax, a proapoptotic protein that has the 
ability to form oligomers on the outer mitochondrial membrane causing membrane 
permeabilization and apoptosis (Lamb & Hardwick, 2013), were surprisingly decreased.  
The reason for this decrease in the levels of Bax is not understood, since equal levels 
were expected as mutant p53 in known to be unable to activate Bax transcription 
(Campomenosi et al., 2001). Nevertheless, this decrease in Bax might explain the low 
levels of cell death that were detected upon treatment of cells with the mushroom 
extract.  
The p53 family has several isoforms and many of the functions of the p53 tumour 
suppressor protein may be shared by other members of this family, such as the p73 
protein (Müller et al., 2006). Therefore, the effect of the extract on the levels on p73 
protein was studied. No difference in p73 protein levels was found, indicating that p73 
is not involved in the effect of this extract (Figure 3D).   
Finally, the levels of p-H2A.X were determined and found to be increased upon 
treatment of the cells with twice the GI50 concentration of the extract (Figure 3E). This 
increase is suggestive of DNA damage and could justify the increase in the p53 levels 
previously found. 
In conclusion, it may be interesting to further study this extract, considering that many 
tumours present mutant p53 tumour suppressor gene and that this extract is capable of 
decreasing cellular proliferation in the absence of functional p53, an event most likely 
triggered by an increase in DNA damage. Nonetheless, further studies regarding the 
cellular effects resulting from the increase in mutant p53 levels need to be carried out, 
since some mutant p53 have gain of function and may lead to a decrease in apoptosis, 
decrease in growth arrest, decrease in senescence and increase in chemoresistance 
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(Strano et al., 2007). Therefore, an increase in mutant p53 may have deleterious cellular 
effects. 
The mechanisms or pathways leading to the observed decrease in cellular proliferation 
may be complex and need to be further studied. We found no evidence of p73 being 
involved in this pathway, at least in the HCT-15 cell line (which presents mutant p53), 
but other p53 family proteins (DeYoung and Ellisen, 2007) may be involved. In 
addition, many studies have demonstrated that Bcl-2 and Bax also have an effect on 
cellular proliferation. For example, bax has been shown to reverse the proliferation 
retarding activities of Bcl-2 (Borner, 1996 and O'Reilly, 1996). Therefore, the decrease 
in Bax levels that were found following treatment with the mushroom extract may be 
related to the observed decrease in cellular proliferation. Further studies need to be 
carried out in order to evaluate this hypothesis. It would be interesting to identify the 
compound or compounds responsible for the biological activity here described. 
Nevertheless, in a previous work we identified and quantified protocatechuic and 
cinnamic acids in S. luteus methanolic extract, and these compounds could possibly be 
related not only to the antioxidant activity reported in that study (Reis et al., 2011), but 
also to the capacity to decrease cellular proliferation in the herein tested colon cancer 
cell line.  
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Table 1. Growth inhibitory activity of different extracts of S. luteus on human tumour 
cell lines and on primary cells of porcine liver.  
 
Tumour cell lines Primary cells 
 
NCI-H460 HCT-15 MCF-7 AGS PLP2 
Boiled water > 400 > 275# > 400 > 400 > 400 
Methanolic 30.33±1.1 17.75±1.6 32.25±5.7 30.30±3.1 > 400 
Ethanolic > 400 > 400 > 400 > 400 > 400 
Results are expressed as GI50 (concentration of extract in µg/mL that causes 50% 
of cell growth inhibition), and show means ± SD of 3 independent experiments 
performed in duplicate. #The GI50 concentration could not be determined but was 
always superior to 275 µg/mL. 
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Table 2. Percentage of  HCT-15 cells undergoing programmed cell death, following 
treatment with the methanolic extract of S. luteus. 
 Time 
 24h 48h 
Blank 0.23±0.27 0.39±0.15 
DMSO 0.25±0.03 0.34±0.23 
GI50 concentration 0.76±0.15* 0.66±0.18 
2×GI50 concentration 1.64±0.45* 1.66±0.31* 
 
Results were determined by TUNEL assay and are the mean ± SD of at least 3 
independent experiments, performed in duplicate. Statistical significance was tested by 
two tailed paired Student’s t-Test using DMSO as a negative control. * Indicates 
p<0.05. Doxorubicin was used as a positive control. The percentage of cells undergoing 
programmed cell death following 24h of treatment with doxorubicin was 1.95 ± 0.61% 
and following 48h of treatment was 17.73 ± 3.41%. 
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Figure 1. Cell cycle analysis of HCT-15 cells treated with the methanolic extract of S. 
luteus. Cell were treated for 24h (A) or 48h (B) with the GI50 (17.75 µg/mL) or twice 
the GI50 concentrations (35.5 µg/mL) of the extract. Untreated cells (blank) and cells 
treated with DMSO (concentration corresponding to 2xGI50 concentration) were used as 
controls. Results are the means ± SD of 3 independent experiments performed in 
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duplicate. Statistical significance was tested by two tailed paired Student’s t-Test using 






Figure 2. Cellular proliferation of HCT-15 cells treated with the methanolic extract of 
S. luteus. Cells were treated for 24h with the GI50 (17.75 µg/mL) or twice the GI50 (35.5 
µg/mL) concentrations of the extract. Untreated cells (Blank) and cells treated with 
DMSO (concentration corresponding to 2×GI50) were used as controls. Results are the 
mean± SD of 3 independent experiments performed in duplicate. Statistical significance 




















































Figure 3. Protein expression of HCT-15 cells treated with the methanolic extract of S. 
luteus. The levels of p53 (A), p21 (B),  Bax (C), p73 (D) and p-H2A.X (E)  of cells 
treated for 48 h with the GI50 (17.75 µg/mL) or twice the GI50 (35.5 µg/mL) 
concentrations of the extract are shown.  Untreated cells (Blank) and cells treated with 
DMSO (concentration corresponding to 2xGI50) were used as controls. Actin was used 
as the loading control. Results are the mean ± SD of 3 independent experiments. 
Statistical significance was tested by two tailed paired Student’s t-Test using DMSO as 
a negative control. * Indicates p<0.05. 
 
 
 
